eMedicine Specialties > Pediatrics: General Medicine > Pulmonology

Hydrocarbon Inhalation Injury

Author: Jason M Kane, MD, FAAP, Assistant Professor of Pediatrics, Northwestern University Feinberg School of Medicine; Attending Physician, Department of Pediatrics, Section of Pediatric Critical Care and Cardiac Intensive Care, Children's Memorial Hospital
Coauthor(s): Emily B Nazarian, MD, Fellow, Department of Pediatrics, Division of Critical Care, University of Rochester Medical Center; Heidi Connolly, MD, Associate Professor of Pediatrics and Psychiatry, University of Rochester; Director, Pediatric Sleep Medicine Services, Strong Sleep Disorders Center
Contributor Information and Disclosures

Updated: Jun 25, 2008

Introduction

Background

Inhalation injury due to hydrocarbons can occur as a result of either accidental or intentional exposure. Inhalant abuse, the deliberate inhalation of hydrocarbons as a form of recreational drug use, has become a significant health issue affecting children. Epidemiologic data state that, among adolescents, inhalants are the second most widely used class of illicit drugs; more than 2 million children aged 12-17 years report using inhalants at least once in their lifetime. Death from intentional inhalation of hydrocarbon fumes is not uncommon and is usually due to sudden cardiac events or CNS depression. The recognition and treatment of inhalant abuse remain challenges for pediatricians and emergency physicians.

Deliberate inhalation of volatile hydrocarbons for their mood-altering effects is popular among adolescents. Their low cost, ready availability, and ease of use contribute to this problem. Volatile hydrocarbons are contained in glues, solvents, lighter fluid, gasoline, and paints. Most inhalants are composed of several compounds, and almost all pressurized aerosol products can be abused because the propellants are volatile hydrocarbons. Inhalation is most commonly achieved by sniffing, huffing, or bagging.1

Pathophysiology

The exact mechanism of action for the volatile substances on the whole is unknown. Two theories have been postulated for the mechanism of action of inhalants. One hypothesis is that the volatile solvents produce a generalized slowing of axonal ion-channel transport by altering the membranes, similar to anesthetic gasses.2 The second theory suggests that potentiation of the GABA receptors occurs; a cross-tolerance between 1,1,1-trichloroethane, toluene, ethanol, barbiturates, and benzodiazepines is noted.3

Recreational abuse of hydrocarbons by inhalation is accomplished in 3 ways: sniffing, huffing, and bagging.

  • Sniffing, the least potent delivery method, is the inhalation of the volatile substance through the nostrils (ie, sniffing glue).
  • Huffing is the placing of a rag soaked with an inhalant such as gasoline or lighter fluid over the nose and mouth.
  • Bagging involves repeated deep inhalations from a plastic or paper bag filled with a particular hydrocarbon such as spray paint or another propellant.

Chronic abusers generally inhale 3-4 times daily for 10-15 minutes each time, although prolonged sessions of inhaling 6-7 hours a day as a group activity have been described. Tolerance and physical dependence can occur, although withdrawal symptoms are only infrequently reported.

Two primary organ systems are affected by inhalation hydrocarbon toxicity: the CNS and the cardiopulmonary system. Volatile hydrocarbons are highly lipid soluble and readily cross the blood-brain barrier. Rapid absorption occurs across the large surface area of the pulmonary vascular bed, and peak blood levels are noted approximately 15-30 minutes after inhalation. Confusion, disorientation, disinhibition, and euphoria are exhibited early. Speech becomes slurred, and motor function becomes impaired, with gait becoming staggered. Hallucinations are frequently described, followed by CNS depression, drowsiness, and sleep. Coma can occur with prolonged or repeated exposures; however, this is unusual because the intentional exposure ceases as the user becomes drowsy.

Sudden sniffing death syndrome was first described by Bass in 1970.4 Death occurs after the user is startled during or soon after inhalation. Hydrocarbons can sensitize the myocardium to endogenous and exogenous catecholamines, which can precipitate ventricular dysrhythmias and sudden death.5,6 In addition, some limited data have shown toxic effects of hydrocarbons directly on the myocardium, and excess catecholamine concentrations may cause an increase in oxygen demand, coronary artery spasm, platelet aggregation, and thrombus formation.7 Numerous case reports also detail acute myocardial infarction as a complication following hydrocarbon inhalation.8,9,10

With acute intoxication, deaths due to asphyxiation from a plastic bag over the head or from aspiration of stomach contents are not unusual. Also, trauma-related injury and motor vehicle accidents have been reported, resulting from disinhibition and disorientation following inhalation.
Other reported complications include renal tubular acidosis with subsequent hypokalemia and hyperchloremia; frostbite with facial injury and burns to the trachea, mainstem bronchi, esophagus, and oral cavity due to intentional inhalation of fluorinated hydrocarbon; bone marrow damage, aplastic anemia, and leukemia due to benzene exposure; and toxic hepatitis due to toluene exposure.11,12,10,13,14 In contrast to pulmonary injury from aspiration of liquid hydrocarbons, direct pulmonary injury from acute inhalation exposure has not been described.

Many solvents, particularly toluene, are lipophilic and readily cross the placenta, resulting in characteristic fetal anomalies that include microcephaly, narrow bifrontal diameter, short palpebral fissures, hypoplastic mid face, wide nasal bridge, abnormal palmar creases, and blunt fingertips. The syndrome of toluene embryopathy closely resembles the phenotypic features found in fetal alcohol syndrome.15,16

With long-term hydrocarbon inhalation, CNS damage occurs, including loss of cognitive functions, gait disturbances, and loss of coordination. Radiographic tests have demonstrated loss of brain mass and white-matter degeneration. Additionally, certain chemicals have been shown to have associations with specific CNS injuries, including peripheral neuropathy, deafness, and optic neuropathy. Other, less common complications of long-term hydrocarbon inhalation include restrictive pulmonary disease, pulmonary hypertension, and reduced diffusion capacity.17,18,19

Pulmonary toxicity can occur as a result of hydrocarbon aspiration. This injury differs from hydrocarbon inhalation injury. The most common clinical scenario of hydrocarbon aspiration is a young child unintentionally ingesting a hydrocarbon-containing compound such as lamp oil or a cleaning solvent. Hydrocarbons cause direct injury to the respiratory epithelium, producing inflammation and bronchospasm. Direct contact with alveolar membranes can lead to hemorrhage, hyperemia, edema, surfactant inactivation, leukocyte infiltration, and vascular thrombosis. The result is poor oxygen exchange, atelectasis, and pneumonitis. For more information, see Toxicity, Hydrocarbons.

Frequency

United States

National surveys of adolescents in the United States have revealed that, after marijuana, inhalants are the most commonly used class of illicit drugs for 8th and 10th graders; inhalants are the third most widely used illicit drugs for 12th graders.20 The low cost, ease of use, and ready availability of organic solvents perpetuate their abuse. Epidemiologic data suggest a decrease in the prevalence of inhalant abuse, but overall abuse rates remain high.

Inhalant abuse by adolescents in the United States is common. In 2000, more than 2 million adolescents aged 12-17 years reported using inhalants at least once in their lifetime.21 Since 1975, the National Institute on Drug Abuse annual survey of high-school seniors has documented a lifetime incidence of inhalant abuse of 15-20%, with the highest prevalence of use being in 8th graders.22

Although the trend of lifetime use decreases between the 8th and 12th grades, these data may underestimate the true lifetime use of older adolescents because many students have dropped out of school by the 12th grade and, thus, are no longer included in the survey.

The typical person who abuses inhalants is a young male of lower socioeconomic class. Overall, males are twice as likely to abuse inhalants as females; however, between the 8th and 12th grades, the difference is less pronounced. Immigrants from Latin America and American Indians have a higher prevalence of use, and blacks have a low prevalence of inhalant abuse. Although inhalant abuse is typically thought of as being most common among adolescents, abuse among adults is also well described, and abuse in children as young as age 4-6 years has been reported.23,24,22

International

The United Kingdom is the only major country in the Western world that tracks inhalant abuse fatalities; an incidence of 2 deaths per week has been documented. In Canada, the patterns of inhalant use are similar to those associated with other illicit substances for experimenters, intermittent users, and long-term abusers. Long-term use tends to be endemic in both the inner-city areas and remote communities, and data show an association between chronic use, lower socioeconomic class, and family dysfunction.

Mortality/Morbidity

Although hydrocarbon inhalation was previously thought to be a benign fad, permanent and significant pulmonary and neurologic sequelae clearly may persist even after abuse has discontinued. Recreational solvent inhalation may account for as much as 2% of all deaths among adolescent males. In the United Kingdom, 15% of deaths caused by inhalants occur as a result of suffocation, 15% are a result of accidental trauma, and 15% are a result of aspiration, whereas the remaining 55% are a result of sudden sniffing death syndrome.25,26 The fact that 22% of victims of sudden sniffing death syndrome had no history of inhalant abuse is of significant concern, demonstrating that death can result from any episode of inhalant abuse.

In the United States, inhalant abuse was responsible for 12.2% of the deaths reported to poison control centers in the group aged 13-19 years. Given that many inhalant-related deaths are never reported to poison control centers, this statistic grossly underestimates the true mortality due to inhalant abuse.22

Ongoing inhalant use has been associated with significant psychosocial pathology, including failure in school and delinquency; a high correlation between poor academic performance and inhalant abuse is noted. In patients with neurologic symptoms who abused toluene as an inhalant, nearly one third showed deficits in orientation, attention, learning, arithmetic calculation, abstraction, construction, and recall.27,23

As solvent abuse becomes chronic, damage to the CNS becomes irreversible, with changes occurring in the cerebellar and cerebral white matter, including demyelination and gliosis. Psychiatric disorders, spasticity, cognitive changes, and secondary Parkinson disease have been reported. Attention deficit and decreased memory retrieval may also occur.28

Race

Previous data suggested the highest inhalant abuse to be among Latin American immigrants. In adolescents aged 12-17 years, inhalant users were more likely to be American Indian or Alaskan Native (13.2%), followed by multiracial (11.2%) and white (9.5%).29,22 Lowest reported rates were among blacks (5.3%) and Asians (6.5%).

Sex

According to data from Wu et al in 2004, the lifetime prevalence rates of inhalant abuse were not significantly different for males and females aged 12-17 years.22

Age

Peak age of inhalant abuse is 14-15 years, with onset of abuse occurring from ages 6-8 years. Use typically declines by the late teenage years; however, some users continue to abuse inhalants into adulthood.

Clinical

History

A high index of suspicion is required because exposure to most volatile substances is not detectible by physical examination and because people who intentionally abuse inhalants initially deny hydrocarbon inhalation. Presentation of a patient with a characteristic odor of gasoline or kerosene likely suggests exposure; however, patients who present with altered mental status or intoxication should be scrutinized for the possibility of inhalation abuse in addition to abuse of other common drugs.

Populations at higher risk should be questioned more carefully; high-risk populations include children and adolescents from families of low socioeconomic status, in whom unemployment and poverty rates are high, as well as those lacking adult supervision.

  • Common symptoms between episodes of abuse include poor social functioning, underachievement at work or school, apathy, chest pain, and thirst.
  • Carefully investigate the possibility of illicit solvent inhalation in all patients presenting with the following unexplained symptoms or factors:
    • Altered mental status, cerebellar dysfunction, peripheral neuropathy
    • Behavioral changes, deteriorating school performance
    • Pulmonary hypertension with or without cor pulmonale
    • Acute rhabdomyolysis
    • Renal tubular acidosis with severe hypokalemia and hypophosphatemia
    • GI symptoms, such as abdominal pain, hematemesis, nausea, and vomiting
    • Mothers of infants with toluene embryopathy
  • Evaluate all patients who present after autoerotic asphyxiation for solvent abuse because such chemicals may be used to relax inhibitions.
  • When inhalant abuse is identified, make efforts to specifically identify the toxins involved because abusers often ingest various solvent-inhalants and frequently misidentify the substances involved. Hydrocarbons are not often part of a routine toxicology screen; therefore, if such an exposure is clinically suspected, the laboratory must be alerted and specific identifying tests must be obtained.

Physical

Patients who have acute decompensation from solvent-inhalant abuse are frequently found near the offending agent; however, many patients who present to medical care have no obvious physical findings to suggest hydrocarbon exposure or inhalant abuse. Some patients may present with subtle signs of abuse, such as paint staining around the mouth or nose. A characteristic odor may be detectable on presentation because a significant proportion of the absorbed chemical exits the body via the lungs. Also, the product may have been spilled onto clothing during use.

Evidence of chronic inhalant abuse may be more subtle. Patients presenting with unexplained peripheral neuropathy and weakness, diffuse GI symptoms, or neuropsychiatric symptoms should raise suspicion of chronic solvent-inhalant abuse. Electrolyte abnormalities, including hypokalemia, hypophosphatemia, and acidosis, should further raise suspicion. However, the nature of these symptoms is not diagnostic of solvent-inhalant abuse; therefore, a very broad differential diagnosis is required. Signs and symptoms are as follows:

  • A single, loud S2 may be evident as a result of pulmonary hypertension.
  • Ventricular arrhythmias or bradycardia may be observed.
  • Discolored urine may be evident from rhabdomyolysis.
  • Adolescents who present with unexplained obtundation or seizures should be examined carefully for evidence of recent solvent-inhalant exposure.
  • Physical findings of recent solvent-inhalant abuse include flecks of paint around the nose and mouth and staining of the fingers, nails, and clothing.
  • A solvent aroma may be present on the breath.
  • Rhinitis, nasal mucosal erosions, epistaxis, hoarse voice, and conjunctivitis may result from local exposure.
  • The acute neurologic effects of inhaled solvents generally wear off within minutes to a few hours, but the effects of more chronic use may persist.
  • Muscle weakness, diffuse GI symptoms, and neuropsychiatric symptoms are 3 major symptom patterns of chronic abuse.

Causes

The common idea that solvent inhalation is innocuous undoubtedly contributes to solvent-inhalant abuse. The wide availability of organic solvents in commonly used household products makes them readily accessible.

  • Commonly abused products
    • Liquids
      • Model Glue
      • Gasoline
      • Contact cement (rubber cement)
      • Lacquers
      • Nail-polish remover
      • Dry-cleaning fluids
    • Aerosols
      • Spray paints
      • Butane fuel, lighter fluid
      • Cooking sprays
      • Cosmetics, hairspray
      • Toiletries, deodorants
  • Chemicals found in abused inhalants
    • Propane
    • Butane
    • n-Hexane
    • Trichloroethylene
    • Freon
    • Benzene
    • Toluene
    • Xylene
    • Acetone
    • Methyl isobutyl ketone

More on Hydrocarbon Inhalation Injury

Overview: Hydrocarbon Inhalation Injury
Differential Diagnoses & Workup: Hydrocarbon Inhalation Injury
Treatment & Medication: Hydrocarbon Inhalation Injury
Follow-up: Hydrocarbon Inhalation Injury
References
Further Reading

References

  1. McHugh MJ. The abuse of volatile substances. Pediatr Clin North Am. Apr 1987;34(2):333-40. [Medline].

  2. Lyon RC, McComb JA, Schreurs J, et al. A relationship between alcohol intoxication and the disordering of brain membranes by a series of short-chain alcohols. J Pharmacol Exp Ther. Sep 1981;218(3):669-75. [Medline].

  3. Jones HE, Balster RL. Inhalant abuse in pregnancy. Obstet Gynecol Clin North Am. Mar 1998;25(1):153-67. [Medline].

  4. Bass M. Sudden sniffing death. JAMA. Jun 22 1970;212(12):2075-9. [Medline].

  5. LoVecchio F, Fulton SE. Ventricular fibrillation following inhalation of Glade Air Freshener. Eur J Emerg Med. Jun 2001;8(2):153-4. [Medline].

  6. Edwards KE, Wenstone R. Successful resuscitation from recurrent ventricular fibrillation secondary to butane inhalation. Br J Anaesth. Jun 2000;84(6):803-5. [Medline].

  7. El-Menyar AA, El-Tawil M, Al Suwaidi J. A teenager with angiographically normal epicardial coronary arteries and acute myocardial infarction after butane inhalation. Eur J Emerg Med. Jun 2005;12(3):137-41. [Medline].

  8. Berkowitz FE, Booth WR. Glue-sniffing in a young child. S Afr Med J. Oct 7 1978;54(15):622. [Medline].

  9. Anderson CE, Loomis GA. Recognition and prevention of inhalant abuse. Am Fam Physician. Sep 1 2003;68(5):869-74. [Medline].

  10. King GS, Smialek JE, Troutman WG. Sudden death in adolescents resulting from the inhalation of typewriter correction fluid. JAMA. Mar 15 1985;253(11):1604-6. [Medline].

  11. Frangides CY, Tzortzatos GV, Koulouras V, et al. Acute massive rhabdomyolysis due to prolonged inhalation of liquid gas. Eur J Emerg Med. Mar 2003;10(1):44-6. [Medline].

  12. Harris D, Mirza Z. Butane encephalopathy. Emerg Med J. Sep 2005;22(9):676-7. [Medline].

  13. Kuspis DA, Krenzelok EP. Oral frostbite injury from intentional abuse of a fluorinated hydrocarbon. J Toxicol Clin Toxicol. 1999;37(7):873-5. [Medline].

  14. Streicher HZ, Gabow PA, Moss AH, et al. Syndromes of toluene sniffing in adults. Ann Intern Med. Jun 1981;94(6):758-62. [Medline].

  15. Arnold GL, Kirby RS, Langendoerfer S, et al. Toluene embryopathy: clinical delineation and developmental follow-up. Pediatrics. Feb 1994;93(2):216-20. [Medline].

  16. Pearson MA, Hoyme HE, Seaver LH, et al. Toluene embryopathy: delineation of the phenotype and comparison with fetal alcohol syndrome. Pediatrics. Feb 1994;93(2):211-5. [Medline].

  17. Devathasan G, Low D, Teoh PC, et al. Complications of chronic glue (toluene) abuse in adolescents. Aust N Z J Med. Feb 1984;14(1):39-43. [Medline].

  18. Aydin K, Sencer S, Demir T, et al. Cranial MR findings in chronic toluene abuse by inhalation. AJNR Am J Neuroradiol. Aug 2002;23(7):1173-9. [Medline].

  19. Borne J, Riascos R, Cuellar H, et al. Neuroimaging in drug and substance abuse part II: opioids and solvents. Top Magn Reson Imaging. Jun 2005;16(3):239-45. [Medline].

  20. Lorenc JD. Inhalant abuse in the pediatric population: a persistent challenge. Curr Opin Pediatr. Apr 2003;15(2):204-9. [Medline].

  21. Kurtzman TL, Otsuka KN, Wahl RA. Inhalant abuse by adolescents. J Adolesc Health. Mar 2001;28(3):170-80. [Medline].

  22. Wu LT, Pilowsky DJ, Schlenger WE. Inhalant abuse and dependence among adolescents in the United States. J Am Acad Child Adolesc Psychiatry. Oct 2004;43(10):1206-14. [Medline].

  23. Uzun N, Kendirli Y. Clinical, socio-demographic, neurophysiological and neuropsychiatric evaluation of children with volatile substance addiction. Child Care Health Dev. Jul 2005;31(4):425-32. [Medline].

  24. Dinwiddie SH. Abuse of inhalants: a review. Addiction. Aug 1994;89(8):925-39. [Medline].

  25. Ashton CH. Solvent abuse. BMJ. Jan 20 1990;300(6718):135-6. [Medline].

  26. Anderson HR, Macnair RS, Ramsey JD. Deaths from abuse of volatile substances: a national epidemiological study. Br Med J (Clin Res Ed). Jan 26 1985;290(6464):304-7. [Medline].

  27. Lowenstein LF. Recent research into glue-sniffing--extent of the problem its repercussions and treatment approaches. Int J Soc Psychiatry. Summer 1985;31(2):93-7. [Medline].

  28. Westermeyer J. The psychiatrist and solvent-inhalant abuse: recognition, assessment, and treatment. Am J Psychiatry. Jul 1987;144(7):903-7. [Medline].

  29. Padilla ER, Padilla AM, Morales A, et al. Inhalant, marijuana, and alcohol abuse among barrio children and adolescents. Int J Addict. Oct 1979;14(7):945-64. [Medline].

  30. Broussard LA. The role of the laboratory in detecting inhalant abuse. Clin Lab Sci. Fall 2000;13(4):205-9. [Medline].

Further Reading

National Institute on Drug Abuse. NIDA Research Report - Inhalant Abuse. National Institutes of Health. Available at http://www.nida.nih.gov/researchreports/inhalants/Inhalants.html

Keywords

hydrocarbon inhalation injury, volatile substance abuse, inhalant abuse, solvent abuse, sniffing, huffing, bagging, solvent, butane, toluene, sudden cardiac events, sudden sniffing death syndrome, ventricular dysrhythmias, sudden death, myocardial infarction, renal tubular acidosis, hypokalemia, hyperchloremia, frostbite, bone marrow damage, aplastic anemia, leukemia, toxic hepatitis, pulmonary injury, microcephaly, narrow bifrontal diameter, short palpebral fissures, hypoplastic mid face, wide nasal bridge, abnormal palmar creases, blunt fingertips, pulmonary hypertension, hydrocarbon aspiration, Parkinson disease, attention deficit, rhabdomyolysis, rhinitis, nasal mucosal erosions, epistaxis, hoarse voice, conjunctivitis, hypophosphatemia, hypercalcemia

Contributor Information and Disclosures

Author

Jason M Kane, MD, FAAP, Assistant Professor of Pediatrics, Northwestern University Feinberg School of Medicine; Attending Physician, Department of Pediatrics, Section of Pediatric Critical Care and Cardiac Intensive Care, Children's Memorial Hospital
Jason M Kane, MD, FAAP is a member of the following medical societies: American Academy of Pediatrics, American College of Chest Physicians, American Thoracic Society, and Society of Critical Care Medicine
Disclosure: Nothing to disclose.

Coauthor(s)

Emily B Nazarian, MD, Fellow, Department of Pediatrics, Division of Critical Care, University of Rochester Medical Center
Emily B Nazarian, MD is a member of the following medical societies: American Academy of Pediatrics
Disclosure: Nothing to disclose.

Heidi Connolly, MD, Associate Professor of Pediatrics and Psychiatry, University of Rochester; Director, Pediatric Sleep Medicine Services, Strong Sleep Disorders Center
Heidi Connolly, MD is a member of the following medical societies: American Academy of Pediatrics, American Thoracic Society, and Society of Critical Care Medicine
Disclosure: Nothing to disclose.

Medical Editor

Girish D Sharma, MD, Associate Professor, Department of Pediatrics, Rush University Medical Center, Rush Children's Hospital; Director of Pediatric Pulmonary Section and Rush Cystic Fibrosis Center
Girish D Sharma, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Chest Physicians, American Thoracic Society, and Royal College of Physicians of Ireland
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine.com, Inc
Disclosure: Pfizer Inc Stock Investment from broker recommendation; Avanir Pharma Stock Investment from broker recommendation

Managing Editor

Charles Callahan, DO, Professor, Deputy Chief of Clinical Services, Walter Reed Army Medical Center
Charles Callahan, DO is a member of the following medical societies: American Academy of Pediatrics, American College of Chest Physicians, American College of Osteopathic Pediatricians, American Thoracic Society, Association of Military Surgeons of the US, and Christian Medical & Dental Society
Disclosure: Nothing to disclose.

CME Editor

Mary E Cataletto, MD, Associate Director, Division of Pediatric Pulmonology, Winthrop University Hospital; Associate Professor, Department of Clinical Pediatrics, State University of New York at Stony Brook
Mary E Cataletto, MD is a member of the following medical societies: American Academy of Pediatrics, American Heart Association, and American Thoracic Society
Disclosure: Nothing to disclose.

Chief Editor

Michael R Bye, MD, Attending Physician, Pediatric Pulmonary Medicine, Columbia University Medical Center; Professor of Clinical Pediatrics, Division of Pulmonary Medicine, Columbia University College of Physicians and Surgeons
Michael R Bye, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Chest Physicians, and American Thoracic Society
Disclosure: Merck Honoraria Speaking and teaching

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.